Botulinum Toxins Type A
Mostrando 1-12 de 67 artigos, teses e dissertações.
-
1. Long-term response of different Botulinum toxins in refractory neurogenic detrusor overactivity due to spinal cord injury
ABSTRACT Purpose To assess the response in spinal cord injured patients alternatively treated with different types and dosages of Botulinum neurotoxin type A (BoNT/A) over 15 years. Material and methods Patients who underwent first BoNT/A from 1999-2001 and practiced intermittent catheterization were included. Baseline 3-day bladder diary (BD) and urodyn
Int. braz j urol.. Publicado em: 2017-08
-
2. Estudo comparativo entre cloridrato de oxibutinina e onabotulinumtoxina em pacientes portadores de lesão medular com hiperatividade do detrusor : avaliação urodinâmica e qualidade de vida = Comparative study between oxybutynin chloride and onabotulinumtoxinA in spinal cord injured patients with detrusor overactivity urodynamic evaluation and quality of life / Comparative study between oxybutynin chloride and onabotulinumtoxinA in spinal cord injured patients with detrusor overactivity : urodynamic evaluation and quality of life
Introdução: O tratamento da incontinência urinária é aspecto importante no processo de reabilitação de pacientes portadores de lesão medular (LM). Objetivos: Os objetivos desse estudo foram avaliar o impacto na qualidade de vida (QV) e nos parâmetros urodinâmicos de pacientes portadores de LM tratados com injeção intradetrusora de onabotulinumtox
IBICT - Instituto Brasileiro de Informação em Ciência e Tecnologia. Publicado em: 22/08/2012
-
3. Tratamento da distonia cervical com fisioterapia: estudo de 20 casos / Cervical dystonia and physical therapy: a case study of 20 subjects
INTRODUÇÃO: Apesar da terapia com toxina botulínica ser o tratamento de escolha para a distonia cervical, admite-se que um tratamento multidisciplinar, agregando a fisioterapia ao tratamento com toxina botulínica, poderia acrescentar maiores benefícios aos pacientes com distonia cervical; sendo assim, o objetivo primário deste estudo foi avaliar o efei
IBICT - Instituto Brasileiro de Informação em Ciência e Tecnologia. Publicado em: 21/05/2012
-
4. Experience with different botulinum toxins for the treatment of refractory neurogenic detrusor overactivity
PURPOSE: To report our experience with the use of the botulinum toxin-A (BoNT/A) formulations Botox® and Prosigne® in the treatment of neurogenic detrusor overactivity (NDO). MATERIALS AND METHODS: At a single institution, 45 consecutive patients with refractory urinary incontinence due to NDO received a single intradetrusor (excluding the trigone) treatme
International braz j urol. Publicado em: 2010-02
-
5. Estudo da Ação da Toxina Botulínica do tipo A na profilaxia da Migrânea Sem Aura / Study of the Action of Botulinum Toxin Type A in the Prophylaxis of Migraine Without Aura
A randomized, double-blind, placebo-controlled study of the use of botulinum toxin type A in the prophylactic treatment of Migraine is presented. Migraine is a common type of primary, benign, episodic headache. It is characterized by pain usually unilateral and throbbing. Other associated symptoms are nausea, sensitivity to light and sound, or irritability.
Publicado em: 2004
-
6. Establishment of a monoclonal antibody recognizing an antigenic site common to Clostridium botulinum type B, C1, D, and E toxins and tetanus toxin.
The partial amino acid sequence of the light-chain (Lc) component of Clostridium botulinum type C1 toxin was determined. The sequence was quite similar to those of the other types of botulinum and tetanus toxins. Nine monoclonal antibodies against botulinum type E toxin were established by immunizing BALB/c mice with type E toxoid or its Lc component. Six an
-
7. Evaluation of neutralizing antibodies to type A, B, E, and F botulinum toxins in sera from human recipients of botulinum pentavalent (ABCDE) toxoid.
Twenty-five serum specimens from personnel immunized with botulinum pentavalent toxoid (ABCDE) had titers of neutralizing antibodies to type A (5.7 to 51.6 IU/ml), type B (0.75 to 18 IU/ml), and type E (0.61 to 10 IU/ml) botulinum toxins. Titers for one type could not be used to predict titers for another type in individuals receiving the toxoid. Cross-neutr
-
8. Dual Toxin-Producing Strain of Clostridium botulinum Type Bf Isolated from a California Patient with Infant Botulism
A retrospective study of Clostridium botulinum strains isolated from patients from California with infant botulism identified the fourth known C. botulinum strain that produces both type B and type F botulinum toxins. This unique strain represented 0.12% of the California infant botulism case isolates from 1976 to 2003. The relative concentrations of type B
American Society for Microbiology.
-
9. Sequence homology between tetanus and botulinum toxins detected by an antipeptide antibody.
The extent of immunological similarity between tetanus toxin and botulinum toxins A, B, C1, and E was studied by using 10 antibodies produced against synthetic peptides representing different sequences of tetanus toxin, mouse antitetanus serum, and human Tetanus Immune Globulin. Antibodies produced against the synthetic peptides recognized tetanus toxin in a
-
10. Correlation between oral toxicity and in vitro stability of Clostridium botulinum type A and B toxins of different molecular sizes.
The in vitro sensitivity to acid and pepsin differed markedly among Clostridium botulinum type A and B toxins of different molecular sizes. The larger the molecular size of the toxin, the higher the resistance to these agents. Tye B derivative toxin was rapidly inactivated, but the progenitor toxins resisted in vitro exposure to rat intestinal juice. The mol
-
11. Comparison of toxins of Clostridium butyricum and Clostridium botulinum type E.
The toxin of Clostridium butyricum strains isolated from two infants with botulism is neutralized by antitoxin for type E botulinum toxin. This toxin and that of a C. botulinum type E strain were purified by the same protocol. Both toxins were Mr 145,000 proteins which, when activated with trypsin, were composed of an H subunit of Mr 105,000 and an L subunit
-
12. Comparison of progenitor toxins of nonproteolytic with those of proteolytic Clostridium botulinum Type B.
A nonproteolytic strain of Clostridium botulinum type B produces two toxins of different molecular weight (16S and 12S) that are indistinguishable from the corresponding toxins of a proteolytic strain in molecular weight and construction but differ in potential toxicity, activation ratio, and hemagglutinability. Successful hybridization between the toxic and